Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NEO Neogenomics Inc
- Stocks
- Healthcare
- NASDAQ: NEO
Price (delayed)
$8.06
Market cap
$1.04B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.61
Enterprise value
$1.3B
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose
Highlights
Neogenomics's gross profit has increased by 17% YoY and by 2.7% QoQ
The revenue rose by 10% YoY
The quick ratio has plunged by 73% YoY but it has grown by 2.2% from the previous quarter
The equity is down by 3.8% year-on-year
Key stats
What are the main financial stats of NEO
Market
Valuations
Earnings
Shares outstanding
128.69M
Market cap
$1.04B
Enterprise value
$1.3B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.17
Price to sales (P/S)
1.53
EV/EBIT
N/A
EV/EBITDA
161.66
EV/Sales
1.93
Revenue
$672.36M
Gross profit
$297.88M
Operating income
-$89.36M
Net income
-$77.59M
EBIT
-$72.1M
EBITDA
$8.02M
Free cash flow
-$32.37M
Per share
Balance sheet
Liquidity
EPS
-$0.61
EPS diluted
-$0.61
Free cash flow per share
-$0.25
Book value per share
$6.91
Revenue per share
$5.28
TBVPS
$5.87
Total assets
$1.6B
Total liabilities
$713.16M
Debt
$604.78M
Equity
$888.27M
Working capital
$294.24M
Debt to equity
0.68
Current ratio
2.05
Quick ratio
1.82
Net debt/EBITDA
32.26
Margins
Efficiency
Dividend
EBITDA margin
1.2%
Gross margin
44.3%
Net margin
-11.5%
Operating margin
-13.3%
Return on assets
-4.8%
Return on equity
-8.6%
Return on invested capital
-10%
Return on capital employed
-5.5%
Return on sales
-10.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NEO stock price
How has the Neogenomics stock price performed over time
Intraday
-0.62%
1 week
-5.29%
1 month
-15.6%
1 year
-45.54%
YTD
-51.09%
QTD
-15.07%
Financial performance
How have Neogenomics's revenue and profit performed over time
Revenue
$672.36M
Gross profit
$297.88M
Operating income
-$89.36M
Net income
-$77.59M
Gross margin
44.3%
Net margin
-11.5%
Neogenomics's operating margin has increased by 21% YoY and by 4.3% from the previous quarter
NEO's net margin is up by 17% YoY and by 3.4% QoQ
Neogenomics's gross profit has increased by 17% YoY and by 2.7% QoQ
The company's operating income rose by 13% YoY and by 3% QoQ
Price vs fundamentals
How does NEO's price correlate with its fundamentals
Growth
What is Neogenomics's growth rate over time
Valuation
What is Neogenomics stock price valuation
P/E
N/A
P/B
1.17
P/S
1.53
EV/EBIT
N/A
EV/EBITDA
161.66
EV/Sales
1.93
The company's EPS rose by 8% YoY
The price to book (P/B) is 62% less than the 5-year quarterly average of 3.1 and 38% less than the last 4 quarters average of 1.9
The equity is down by 3.8% year-on-year
The price to sales (P/S) is 73% lower than the 5-year quarterly average of 5.6 and 43% lower than the last 4 quarters average of 2.7
The revenue rose by 10% YoY
Efficiency
How efficient is Neogenomics business performance
The company's return on sales rose by 22% YoY and by 4.5% QoQ
NEO's ROIC is down by 16% year-on-year and by 5% since the previous quarter
The return on assets rose by 4% year-on-year
The return on equity has increased by 3.4% year-on-year
Dividends
What is NEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NEO.
Financial health
How did Neogenomics financials performed over time
The total assets is 125% greater than the total liabilities
NEO's current ratio has plunged by 73% YoY but it is up by 3.5% from the previous quarter
The quick ratio has plunged by 73% YoY but it has grown by 2.2% from the previous quarter
NEO's debt is 32% lower than its equity
The equity is down by 3.8% year-on-year
The debt to equity rose by 3% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.